Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, specifically related to the company's financial disclosures and performance claims [1][2]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Performance - The lawsuit alleges that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as claimed, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Nvidia (NVDA 0.53%) is one of the hottest stocks on the market today. Over the past five years, Nvidia shares have soared in value by nearly 1,500%, including another 20% in the last 12 months.Think the run is over? Think again. Nvidia stock remains far cheaper than most investors realize due to one critical factor.Nvidia's profits will rise for decades to comeThe artificial intelligence (AI) revolution is in full swing. But we're still in the early innings. In 2023, the United Nations estimated the global ...

A major burden in life science remains the cost associated with drug development. Estimated at $1B to bring a drug from preclinical research to commercialization, solutions are needed to reduce those costs. Among these solutions, Model-Informed Drug Development (MIDD) is one ofAt ELAM1, we empower financial professionals and investors with the scientific and clinical expertise required to navigate the complexities of the healthcare sector. By bridging the gap between cutting-edge science and financial strat ...

Core Insights - NeOnc Technologies Holdings, Inc. has received formal approval from its Board of Directors for a strategic transaction with Quazar Investment, marking a significant step towards closing the deal [1][2][3] Company Overview - NeOnc Technologies is a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers, utilizing its NEO™ drug development platform [5] - The company’s proprietary chemotherapy agents, including NEO100™ and NEO212™, are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [5] Strategic Partnership - The Board's unanimous approval allows NeOnc to participate in a $50 million equity investment and expansion into the MENA region under a non-binding term sheet with Quazar [2][3] - Quazar plans to lead a capital formation round priced at $25 per share, with 70% of proceeds allocated to acquiring NeOnc common stock and 30% for clinical trials and infrastructure development in the UAE and MENA region [3] Transaction Milestones - The transaction requires NeOnc to meet five milestones, with the current Board approval being the first of these [2][4] - NeOnc has 120 days to satisfy the remaining conditions necessary for closing the transaction [4] Future Developments - The strategic partnership aims to establish a strong operational presence in the MENA region and accelerate the clinical development of NeOnc's core assets [3] - Key future actions include the legal formation of NuroMENA and NuroCure in Abu Dhabi, execution of a Sub-License Agreement, finalization of offering documents, and approval of a comprehensive business plan [8]

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, stemming from allegations of overstating cost savings and revenue projections related to transition services agreements following its spin-off from Labcorp [1][2][4]. Company Overview - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Allegations and Financial Impact - The lawsuit claims that Fortrea exaggerated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as previously thought, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing financial results for Q4 and full year 2024, stating that pre-spin projects had lower revenue and profitability than expected, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Transaction unlocks significant value to shareholdersResulting net cash position will provide greater flexibility to carry out business strategy MONTREAL, July 10, 2025 (GLOBE NEWSWIRE) -- Supremex Inc. (“Supremex” or the “Company”) (TSX: SXP), a leading North American manufacturer and marketer of envelopes and a growing provider of paper-based packaging solutions, announced today that it completed a sale-leaseback transaction in respect of its two owned properties for gross proceeds of $53.0 million, subje ...

Velos Markets的资产覆盖能力如同一个精心设计的"金融魔方"，通过外汇、差价合约（CFD）和加密货币三大支柱，将全球市场浓缩于用户指 尖。平台支持EUR/USD、GBP/JPY等主流货币对外汇交易，同时涵盖新兴市场货币组合，形成一张动态的"全球汇率波动地图"。对于偏好避险资 产的投资者，现货黄金交易支持T+0机制（即当天买卖无限制），配合杠杆功能，允许用户以1:100的比例撬动交易规模，用较小的本金捕捉贵金 属市场的波动机会。 全息市场分析：穿透数据迷雾的CT扫描仪 平台的核心优势之一在于其"全息市场分析"系统，这一工具如同金融市场的CT扫描仪，整合宏观经济数据、行业动态及技术指标，生成多维度投 资洞察。例如，黄金投资者可同时查看美元指数波动、地缘政治事件与矿业公司财报数据，形成立体化决策依据。技术分析者则可调用内置的40 余种技术指标，结合自定义算法回测功能，验证交易策略的有效性。 针对不同投资者类型，平台开发了差异化的策略工具箱： 新手辅助模式：启用"全息分析建议引擎"，输入投资金额、风险偏好和持有周期后，系统会生成包含外汇、黄金、股指的平衡型组合模板； 操作界面拆解：从开户到交易的十二格台阶 ...

NEENAH, WI, July 09, 2025 (GLOBE NEWSWIRE) -- Plexus Corp. (NASDAQ: PLXS) announced today it will release its fiscal third quarter 2025 results after market close on Wednesday, July 23, 2025. Plexus’ management will host a conference call to discuss its fiscal third quarter results on Thursday, July 24, 2025 at 8:30 a.m. Eastern Time. An audio webcast of the call and accompanying slides will be available in the investor relations section of the company website, plexus.com. What:Plexus Fiscal 2025 Q3 Earning ...

Group 1: Dividend Attractiveness - Federal Realty offers an attractive dividend yield of 4.6%, significantly higher than the S&P 500's yield of approximately 1.3% and the average REIT yield of 4.1% [2] - The company has increased its dividend annually for 57 consecutive years, earning it the title of Dividend King, a designation for companies that have raised dividends for at least five decades [4] Group 2: Company Overview - Federal Realty is a retail-focused real estate investment trust (REIT) that primarily invests in strip malls and mixed-use developments, catering to consumer needs [6] - The company owns around 100 high-quality properties, which are strategically located in markets with larger populations and greater wealth compared to its peers [7] Group 3: Active Management Strategy - Federal Realty actively manages its portfolio by buying and selling properties, continually investing in them to enhance value [8] - This proactive approach contributes to its impressive dividend record, as the company focuses on constant improvement rather than merely collecting rent [9] Group 4: Market Position - Federal Realty is not frequently available at discounted prices, typically only during significant economic downturns, but its current dividend yield of 4.7% remains historically attractive [10]

Core Insights - NeOnc Technologies Holdings, Inc. has been included in the Russell Microcap® Index, which is a significant recognition of the company's growth and commitment to shareholder value [1][3] - The Russell Microcap® Index includes companies with an average market capitalization of approximately $640 million, covering stocks ranging from about $30 million to $3 billion [3][4] - NeOnc is focused on advancing its Phase II clinical trials for CNS cancers and expanding into the MENA region through a proposed partnership with Quazar [3] Company Overview - NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for central nervous system cancers and disorders [1][6] - The company utilizes the NEO™ drug development platform, which has produced a portfolio of novel drug candidates with patent protections extending to 2038 [6] - NeOnc's therapeutics, NEO100™ and NEO212™, are currently in Phase II human clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [6] Industry Context - The Russell US Indexes reconstitution ranks the 4,000 largest US stocks by total market capitalization, and membership in the Russell Microcap® Index is valid for one year [2][4] - Russell indexes are widely utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [4]